Sedana Medical
ISIN: SE0015988373 | Ticker: SEDANA | LEI: 549300FQ3NJRI56LCX32
Country: Sweden
Sedana Medical is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical product Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.
Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm and is headquartered in Stockholm, Sweden.
1999
Served areaWorldwide
Headcount85
HeadquartersVendevägen 89, 18232 Danderyd – Sweden
| Line item in (sek) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Assets | N/A | 1,167,580,000.00 | 1,081,588,000.00 |
| Noncurrent Assets | N/A | 286,839,000.00 | 408,172,000.00 |
| Machinery | N/A | 1,309,000.00 | 955,000.00 |
| Copyrights Patents And Other Industrial Property Rights Service And Operating Rights | N/A | 1,786,000.00 | 2,849,000.00 |
| Deferred Tax Assets | N/A | 23,000.00 | 29,000.00 |
| Other Noncurrent Financial Assets | N/A | 42,000.00 | 46,000.00 |
| Current Assets | N/A | 880,741,000.00 | 673,416,000.00 |
| Inventories | N/A | 11,093,000.00 | 38,597,000.00 |
| Current Trade Receivables | N/A | 20,345,000.00 | 15,849,000.00 |
| Current Prepayments And Current Accrued Income Other Than Current Contract Assets | N/A | 7,115,000.00 | 6,017,000.00 |
| Current Tax Assets Current | N/A | 410,000.00 | 514,000.00 |
| Other Current Nonfinancial Assets | N/A | 5,597,000.00 | 4,697,000.00 |
| Cash | 376,171,000.00 | 836,181,000.00 | 607,742,000.00 |
| Equity And Liabilities | N/A | 1,167,580,000.00 | 1,081,588,000.00 |
| Equity | 551,094,000.00 | 1,101,456,000.00 | 1,029,156,000.00 |
| Issued Capital | N/A | 2,483,000.00 | 2,483,000.00 |
| Retained Earnings | N/A | -123,606,000.00 | -197,113,000.00 |
| Additional Paidin Capital | N/A | 1,222,395,000.00 | 1,226,435,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 1,101,456,000.00 | 1,029,155,000.00 |
| Liabilities | N/A | 66,124,000.00 | 52,433,000.00 |
| Noncurrent Liabilities | N/A | 4,642,000.00 | 3,576,000.00 |
| Current Liabilities | N/A | 61,482,000.00 | 48,857,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 15,036,000.00 | 11,270,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | 19,744,000.00 | 22,932,000.00 |
| Current Tax Liabilities Current | N/A | 3,997,000.00 | 2,559,000.00 |
| Other Current Liabilities | N/A | 18,473,000.00 | 6,929,000.00 |
| Line item in (sek) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue From Sale Of Goods | 159,152,000.00 | 122,865,000.00 |
| Other Income | 4,013,000.00 | 13,319,000.00 |
| Profit Loss From Operating Activities | -61,493,000.00 | -105,887,000.00 |
| Finance Income | 11,285,000.00 | 48,300,000.00 |
| Finance Costs | 7,163,000.00 | 15,346,000.00 |
| Profit Loss Before Tax | -57,371,000.00 | -72,933,000.00 |
| Income Tax Expense Continuing Operations | 595,000.00 | 574,000.00 |
| Profit Loss Attributable To Owners Of Parent | -57,966,000.00 | -73,507,000.00 |
| Line item in (sek) | 01.01.2022 | 01.01.2023 |
|---|---|---|
| Adjustments For Decrease Increase In Inventories | -2,296,000.00 | -27,504,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -4,080,000.00 | -863,000.00 |
| Interest Paid Classified As Operating Activities | 243,000.00 | 255,000.00 |
| Interest Received Classified As Operating Activities | 0.00 | 3,580,000.00 |
| Cash Flows From Used In Operating Activities | -41,221,000.00 | -115,433,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 5,192,000.00 | 735,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 105,063,000.00 | 137,048,000.00 |
| Cash Flows From Used In Investing Activities | -110,255,000.00 | -137,783,000.00 |
| Proceeds From Issuing Shares | 614,900,000.00 | 0.00 |
| Proceeds From Issuing Other Equity Instruments | 1,696,000.00 | 3,590,000.00 |
| Payments Of Other Equity Instruments | 0.00 | 490,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 3,579,000.00 | 4,510,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | 0.00 | -97,000.00 |
| Cash Flows From Used In Financing Activities | 605,071,000.00 | -1,507,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 453,595,000.00 | -254,722,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 6,415,000.00 | 26,283,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 29.08.22 | Christoffer Björn Rosenblad | Other | Buy | SEK 232,000.00 |
| 29.08.22 | Christoffer Björn Rosenblad | Other | Sell | SEK 115,000.00 |
| 21.07.22 | Hilde Furberg | Other | Buy | SEK 64,288.44 |
| 28.04.22 | Johan Spetz | Other | Buy | SEK 223,615.21 |
| 28.04.22 | Johannes Doll | Other | Buy | SEK 209,520.60 |
| 28.04.22 | Christoffer Björn Rosenblad | Other | Buy | SEK 161,400.00 |
| 03.12.21 | Johannes Doll | Other | Buy | SEK 1,000,180.00 |
| 20.09.21 | Ola Gunnar Magnusson | Other | Sell | SEK 2,943,000.00 |
SE0015988373
LEI549300FQ3NJRI56LCX32
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.